HIV-1 Evolution and Drug Resistance Among Patients Receiving ART in San Mateo County, California, 1997-2010 S. Dalai MSc, S. Sethi MSc, V. Levy MD, D.

Slides:

Advertisements

Similar presentations

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

Advertisements

An epidemic in transition: impacts of migration and local networks on HIV sequence diversity and infection transmission in Australia

High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.

The effect of changes in Kenya HIV guidelines on proportion of patients on ART and patient characteristics at initiation in Lumumba Health Centre, Western.

Objective of the DAP A) Specify an analysis plan that can be applied to a wide variety of clinical HIV resistance studies. B) Include both Intervention.

Inaugural Conference of the African Health Economics and Policy Association (AfHEA) Accra - Ghana, 10th - 12th March 2009 Patent medicines vendors a resource.

Mary Foote MD, MPH 1 Infectious Disease Fellow Anne Spaulding MD, MPH 1,2 1 Emory University Schools of Medicine and 2 Public Health Atlanta, Georgia Georgia.

HIV INTERVENTION FOR PROVIDERS (HIP) Principal Investigators:  Carol Dawson Rose, RN, Ph.D. and Grant Colfax, MD. Co-Investigators:  Cynthia Gomez, Ph.D.,

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.

Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Presentation Title Presenter(s) Centers for Disease Control and Prevention AIDS Turning the Tide Together.

Family Medicine Residency of Idaho HIV Training Track.

ABSTRACT Introduction: HIV infection is growing relatively fast among seniors. Among the clinical implications are that older patients have less ability.

Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

Effectiveness of Depression Care Management in a Multiple Disease Care Management Model Bruce Friedman, Ph.D. Departments of Community and Preventive Medicine,

Case 1: 23-year-old Male Student Clinical Director, Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical.

Treat Asia Quality Assurance Scheme Supported by AMFAR and coordinated by the National Reference Laboratory in Australia Sally Land.

1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.

M. Ekstrand 1,2,3, A. Shet 2,4, S. Chandy 4, G. Singh 4, R. Shamsundar 4, V. Madhavan 5, S. Saravanan 5, N. Kumarasamy 5 1 University of California, San.

Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.

TITAN = TMC114/r In Treatment-experienced pAtients Naïve to lopinavir

The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.

Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation J. M. Schapiro, J. Vingerhoets, S.

How Does Antiretroviral Therapy Affect HIV Mutation and Vice Versa? Arlin Toro Devin Iimoto Devin Iimoto.

Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.

SCHOOL OF NURSING UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Not Ready for Prime Time? A Web-Based SBIRT Intervention in an Urban Safety-Net HIV Clinic Carol.

High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:

Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.

National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/poster: TUPDC0103.

Will Drug Resistance Jeopardize the National HIV Drug Resistance Programme? Prof. Tulio de Oliveira Africa Centre for Health and Population Studies, University.

Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.

Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.

Management of NRTI Resistance

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Phar. Nhat Mang/ Roche Vietnam

Accumulation of Protease Mutations Among Patients on Non-Suppressive 2 nd -Line ART in Nigeria H. Rawizza, B. Chaplin, S. Meloni, P. Okonkwo, P. Kanki.

The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.

Lessons Learned and Novel Investigation Techniques in Response to a Large Community Outbreak of HIV-1 infection Philip J. Peters MD HIV Testing and Biomedical.

Linking Electronic Health Records Across Institutions to Understand Why Women Seek Care at Multiple Sites for Breast Cancer Caroline A. Thompson, PhD,

INVESTIGATING THE FITNESS BENEFIT OF REVERSE TRANSCRIPTASE (RT) MUTATION A62V CO-OCCURRING WITH M184V AND K65R IN HIV-1 SUBTYPE C Duncan T Njenda (MSc)

Henry Masur, MD Bethesda, Maryland

From Aggregate Indicators to Impacting Patients - Data Use to Inform Treatment and Improve Care Ian Wanyeki Track 1.0 Implementers Meeting Dar Es Salaam.

HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,

PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE

Durban, July 20th 2016 Ruggero Giuliani MSF - Mozambique

Emory University School of Medicine Department of Medicine

TB- HIV Collaborative activities in Romania- may 2006 status

Virological and immunological efficacy of regimen including MVC

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

BIRUTE SEMENAITE, MEDICAL DIVISION OF THE PRISON DEPARTMENT

CAPRISA Advanced Clinical Care Presented by: Nesri Padayatchi

Introduction Results Objectives Methods Conclusion Funding

A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova

Genomes and Their Evolution

Switch to E/C/F/TAF + DRV

Summary Sheet Figures and Maps

Using Whole Genome Sequencing Analysis in California

Background. Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance.

Silvia Bertagnolio, MD HIV Department World Health Organization

Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs N Margot, R Ram, IR McNicholl, R Haubrich, C Callebaut.

Dr. Grace Namayanja – Kaye 24 July 2019

For a healthy Zambia.

Share your thoughts on this presentation with #IAS2019

Share your thoughts on this presentation with #IAS2019

Presentation transcript:

HIV-1 Evolution and Drug Resistance Among Patients Receiving ART in San Mateo County, California, S. Dalai MSc, S. Sethi MSc, V. Levy MD, D. Israelski MD, D. Katzenstein MD Division of Infectious Disease Stanford University, USA Primary contact: 6 th IAS Conference, Rome, Italy

Background and Methods In a community public health treatment program 75/306 patients (25%) remained viremic on ART Paired RT/protease sequences from 75 patients were analyzed to determine vEvol over a median time of 11 months using a best-fit nucleotide substitution model implemented in PAUP. DRM and genotypic susceptibility score (GSS) were determined using HIVSEQ (Stanford Drug Resistance Database). DRMs were correlated using permutation testing to control for a false discovery rate. Is HIV-1 viral evolutionary rate (vEvol) associated with drug class, drug resistance mutations (DRMs) and/or RNA VL? REFERRAL TO SMMC INITIATION OF ART (n=306) SEQUENCE #1SEQUENCE #2 RNA #1RNA #2 vEvol, GSS, DRMs Mean VL n=75 patients; t=11 months

HIV-1 viral evolution is associated with increased RNA VL and presence of PI DRMs

Greater viral evolution in patients with history of PI-exposure no PI no PI-exp

Viral evolution is associated with reduced ARV susceptibility

Correlated DRM pairs associated with increased viral evolution

Conclusions Repeat HIV-1 RNA genotyping in viremic Rx-experienced patients in San Mateo revealed RT/Pr DRMs in 75% and evolutionary changes in 90%. Viral evolution is associated with higher RNA VL, exposure to PI drugs, the co-occurrence of specific DRMs, and reduced genotypic susceptibility to all ARV classes Future analyses will characterize the complex interactions among evolutionary change, DRMs, and reduced drug susceptibility We would like to thank the following: – Patients, physicians, and staff at San Mateo Medical Center – Stanford HIV Drug Resistance Database team; – The Howard Hughes Medical Institute, California HIV Research Program, the Soros Foundation, and the Stanford Medical Scientist Training Program for financial support THANK YOU!